EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma

Arunkumar Krishnan iD, Diptasree Mukherjee

Translational Gastroenterology and Hepatology · 2026-07 · 11 · 77-77

DOI: 10.21037/tgh-2026-0046 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-07. Verfasst von Arunkumar Krishnan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GM-CSF-secreting pancreatic tumor vaccine (GVAX)Pancreatic ductal adenocarcinoma (PDAC)adjuvant immunotherapystereotactic body radiation therapy (SBRT)tumor microenvironment

Autor:innen und Institutionen

  • Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA.

ORCID-Profile: Arunkumar Krishnan

Zitieren

APA

Krishnan, A., & Mukherjee, D. (2026). Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma. Translational Gastroenterology and Hepatology, 11, 77-77. https://doi.org/10.21037/tgh-2026-0046

Vancouver

Krishnan A, Mukherjee D. Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma. Translational Gastroenterology and Hepatology. 2026;11:77-77. doi:10.21037/tgh-2026-0046

BibTeX
@article{Krishnan2026,
  author = {Krishnan, Arunkumar and Mukherjee, Diptasree},
  title = {Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma},
  journal = {Translational Gastroenterology and Hepatology},
  year = {2026},
  volume = {11},
  pages = {77--77},
  doi = {10.21037/tgh-2026-0046}
}
Kostenlos starten →